EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Tumor- and circulating-free DNA methylation identifies clinically relevant small cell lung cancer subtypes

Simon Heeke, Carl M Gay, Marcos R Estecio, Hai Tran, Benjamin B Morris, Bingnan Zhang, Ximing Tang, Maria Gabriela Raso, Pedro Rocha, Siqi Lai, Edurne Arriola, Paul Hofman und 30 weitere

Cancer Cell · 2024-02 · 42 (2) · 225-237.e5

DOI: 10.1016/j.ccell.2024.01.001 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Cell, 2024-02. Verfasst von Simon Heeke und 41 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Hauptthemen laut MEDLINE: Small Cell Lung Carcinoma, Lung Neoplasms, Cell-Free Nucleic Acids. Die Arbeit wurde bisher 143-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, Medical Research Council, Wellcome Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Small cell lung cancer (SCLC) is an aggressive malignancy composed of distinct transcriptional subtypes, but implementing subtyping in the clinic has remained challenging, particularly due to limited tissue availability. Given the known epigenetic regulation of critical SCLC transcriptional programs, we hypothesized that subtype-specific patterns of DNA methylation could be detected in tumor or blood from SCLC patients. Using genomic-wide reduced-representation bisulfite sequencing (RRBS) in two cohorts totaling 179 SCLC patients and using machine learning approaches, we report a highly accurate DNA methylation-based classifier (SCLC-DMC) that can distinguish SCLC subtypes. We further adjust the classifier for circulating-free DNA (cfDNA) to subtype SCLC from plasma. Using the cfDNA classifier (cfDMC), we demonstrate that SCLC phenotypes can evolve during disease progression, highlighting the need for longitudinal tracking of SCLC during clinical treatment. These data establish that tumor and cfDNA methylation can be used to identify SCLC subtypes and might guide precision SCLC therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Small Cell Lung CarcinomaLung NeoplasmsCell-Free Nucleic AcidsHumansDNA MethylationEpigenesis, GeneticBiomarkers, Tumor

Stichwörter der Autor:innen

DNA methylationSCLCbiomarkercfDNActDNAepigeneticsgene expressionliquid biopsylung cancersubtyping

Substanzen

Cell-Free Nucleic AcidsBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Epigenetic and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Department of Translational Molecular Pathology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Medical Oncology Department, Hospital del Mar, Barcelona, Spain.
  • Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Graduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center UTHealth Houston, Houston, TX, USA.
  • Laboratory of Clinical and Experimental Pathology, IHU RespirERA, Nice Hospital, University Côte d'Azur, Nice, France.

Förderung

  • NCI NIH HHS
  • Medical Research Council
  • Wellcome Trust
  • UKRI Medical Research Council
  • Horizon 2020
  • Cancer Prevention and Research Institute of Texas
  • Albert Einstein Cancer Center
  • Cancer Research UK

Zitieren

APA

Heeke, S., Gay, C. M., Estecio, M. R., Tran, H., Morris, B. B., Zhang, B., Tang, X., Raso, M. G., Rocha, P., Lai, S., Arriola, E., Hofman, P., Hofman, V., Kopparapu, P., Lovly, C. M., Concannon, K., De Sousa, L. G., Lewis, W. E., Kondo, K., …, & Heymach, J. V. (2024). Tumor- and circulating-free DNA methylation identifies clinically relevant small cell lung cancer subtypes. Cancer Cell, 42(2), 225-237.e5. https://doi.org/10.1016/j.ccell.2024.01.001

Vancouver

Heeke S, Gay CM, Estecio MR, Tran H, Morris BB, Zhang B, et al. Tumor- and circulating-free DNA methylation identifies clinically relevant small cell lung cancer subtypes. Cancer Cell. 2024;42(2):225-237.e5. doi:10.1016/j.ccell.2024.01.001

BibTeX
@article{Heeke2024,
  author = {Heeke, Simon and Gay, Carl M and Estecio, Marcos R and Tran, Hai and Morris, Benjamin B and Zhang, Bingnan and Tang, Ximing and Raso, Maria Gabriela and Rocha, Pedro and Lai, Siqi and Arriola, Edurne and Hofman, Paul and Hofman, Veronique and Kopparapu, Prasad and Lovly, Christine M and Concannon, Kyle and De Sousa, Luana Guimaraes and Lewis, Whitney Elisabeth and Kondo, Kimie and Hu, Xin and Tanimoto, Azusa and Vokes, Natalie I and Nilsson, Monique B and Stewart, Allison and Jansen, Maarten and Horváth, Ildikó and Gaga, Mina and Panagoulias, Vasileios and Raviv, Yael and Frumkin, Danny and Wasserstrom, Adam and Shuali, Aharona and Schnabel, Catherine A and Xi, Yuanxin and Diao, Lixia and Wang, Qi and Zhang, Jianjun and Van Loo, Peter and Wang, Jing and Wistuba, Ignacio I and Byers, Lauren A and Heymach, John V},
  title = {Tumor- and circulating-free DNA methylation identifies clinically relevant small cell lung cancer subtypes},
  journal = {Cancer Cell},
  year = {2024},
  volume = {42},
  number = {2},
  pages = {225--237.e5},
  doi = {10.1016/j.ccell.2024.01.001}
}
Kostenlos starten →